AI Is About to Simulate Human Biology

Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed? A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.

This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold.In this episode, Jean-Philippe covers:
• Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development.
• How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction.
• Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine.
• How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT)
• What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments.

More videos like this:

Currently no more videos like this.